Anti-CD45 radioimmunotherapy with90Y but not177Lu is effective treatment in a syngeneic murine leukemia model

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Orozco, Johnnie J ^a,b   Balkin, Ethan R ^b   Gooley, Ted A ^a   Kenoyer, Aimee ^a   Hamlin, Donald K ^b   Wilbur, D Scott ^b   Fisher, Darrell R ^c   Hylarides, Mark D ^a   Shadman, Mazyar ^a,b   Green, Damian J ^a,b   Gopal, Ajay K ^a,b   Press, Oliver W ^a,b   Pagel, John M ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Dade Moeller Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; TETRAXETAN; YTTRIUM 90; PTPRC PROTEIN, HUMAN; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW TOXICITY; CONTROLLED STUDY; DOSIMETRY; FEMALE; HEMATOLOGIC MALIGNANCY; LIVER TOXICITY; MOUSE; MURINE LEUKEMIA; NEPHROTOXICITY; NONHUMAN; RADIOIMMUNOTHERAPY; SPLEEN; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; HUMAN; IMMUNOLOGY; KIDNEY; LEUKEMIA, MYELOID; PATHOLOGY; RADIATION RESPONSE; SCINTISCANNING; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

MURINAE; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; LEUKEMIA, MYELOID; MICE; RADIOIMMUNOTHERAPY; RADIONUCLIDE IMAGING; SPLEEN; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84919338324     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113601     Document Type: Article

References (36)

1. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, et al. (1990) Allogeneic Marrow Transplantation in Patients with Acute Myeloid-Leukemia in 1st Remission- a Randomized Trial of 2 Irradiation Regimens. Blood. pp. 1867-1871.
2. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, et al. (1991) Allogeneic Marrow Transplantation in Patients with Chronic Myeloid-Leukemia in the Chronic Phase- a Randomized Trial of 2 Irradiation Regimens. Blood 77: 1660-1665.
3. Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, et al. (1998) Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 92: 1455-1456.
4. Matthews DC, Appelbaum FR, Eary JF, Hui TE, Fisher DR, et al. (1991) Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood 78: 1864-1874.
5. Rosen ST, Zimmer AM, Goldmanleikin R, Gordon LI, Kazikiewicz JM, et al. (1987) Radioimmunodetection and Radioimmunotherapy of Cutaneous T-cell Lymphomas using an I-131-Labeled Monoclonal-Antibody- an Illinois Cancer Council Study. Journal of Clinical Oncology 5: 562-573.
6. Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garinchesa P, et al. (1990) A Phase-1 Toxicity, Pharmacology, and Dosimetry Trial of Monoclonal-Antibody OKB7 in Patients with Non-Hodgkins-Lymphoma- Effects of Tumor Burden and Antigen Expression. Journal of Clinical Oncology 8: 792-803.
7. Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, et al. (1990) Radioimmunotherapy of Human B-cell Lymphoma with Y-90-Conjugated AntiIdiotype Monoclonal-Antibody. Cancer Research 50: S1022-S1028.
8. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, et al. (1991) Targeting, Dosimetry, and Radioimmunotherapy of B-cell Lymphomas with Iodine-131-labeled LL2 Monoclonal-Antibody. Journal of Clinical Oncology 9: 548-564.
9. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, et al. (1993) Radiolabeled-antibody Therapy of B-cell Lymphoma with Autologous Bone-Marrow Support. New England Journal of Medicine 329: 1219-1224.
10. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, et al. (1993) Dose-escalation Trial of M195 Labeled with I-131 for Cytoreduction and Marrow Ablation in Relapsed or Refractory Myeloid Leukemias. Journal of Clinical Oncology 11: 294-303.
11. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, et al. (1999) Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94: 1237-1247.
12. Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, et al. (2006) I-131-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107: 2184-2191.
13. Bunjes DW, Buchmann I, Duncker C, Seitz U, Kotzerke J, et al. (2001) T-cell depleted allogeneic stem cell transplantation after intensified conditioning with Re-188 labelled anti-CD66 monoclonal antibody in patients with high-risk acute leukemia: Long-term follow-up and factors affecting outcome. Blood 98: 197A-197A.
14. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, et al. (2003) Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplantation 32: 549-556.
15. Nakano A, Harada T, Morikawa S, Kato Y (1990) Expression of Leukocyte Common Antigen (CD45) on Various Human Leukemia Lymphoma Cell-Lines. Acta Pathologica Japonica 40: 107-115.
16. Taetle R, Ostergaard H, Smedsrud M, Trowbridge I (1991) Regulation of CD45 Expression in Human Leukemia-Cells. Leukemia 5: 309-314.
17. van der Jagt RHC, Badger CC, Appelbaum FR, Press OW, Matthews DC, et al. (1992) Localization of Radiolabeled Antimyeloid Antibodies in a Human Acute Leukemia Xenograft Tumor Model. Cancer Research 52: 89-94.
18. Omary MB, Trowbridge IS, Battifora HA (1980) Human Homolog of Murine T200 Glycoprotein. Journal of Experimental Medicine 152: 842-852.
19. Pagel JM, Hedin N, Drouet L, Wood BL, Pantelias A, et al. (2008) Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 111: 2261-2268.
20. Pagel JM, Kenoyer AL, Back T, Hamlin DK, Wilbur DS, et al. (2011) Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 118: 703-711.
21. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, et al. (2001) A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98: 2535-2543.
22. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, et al. (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101: 2340-2348.
23. Fisher DR, Badger CC, Breitz H, Eary JF, Durham JS, et al. (1991) Internal Radiation-Dosimetry for Clinical-Testing of Radiolabeled Monoclonal-Antibodies. Antibody Immunoconjugates and Radiopharmaceuticals 4: 655-664.
24. Hui TE, Fisher DR, Kuhn JA, Williams LE, Nourigat C, et al. (1994) A Mouse Model for Calculating Cross-Organ Beta-Doses from Yttrium-90-labeled Immunoconjugates. Cancer 73: 951-957.
25. Beatty BG, Kuhn JA, Hui TE, Fisher DR, Williams LE, et al. (1994) Application of the Cross-Organ Beta-Dose Method for Tissue Dosimetry in Tumor-Bearing Mice Treated with a Y-90 Labeled Immunoconjugate. Cancer 73: 958-965.
26. Robertson R, Germanos MS, Manfredi MG, Smith PG, Silva MD (2011) Multimodal Imaging with F-18-FDG PET and Cerenkov Luminescence Imaging After MLN4924 Treatment in a Human Lymphoma Xenograft Model. Journal of Nuclear Medicine 52: 1764-1769.
27. Ruggiero A, Holland JP, Lewis JS, Grimm J (2010) Cerenkov Luminescence Imaging of Medical Isotopes. Journal of Nuclear Medicine 51: 1123-1130.
28. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, et al. (2009) Optical imaging of Cerenkov light generation from positron-emitting radiotracers. Physics in Medicine and Biology 54: N355-N365.
29. Mitchell GS, Gill RK, Boucher DL, Li CQ, Cherry SR (2011) In vivo Cerenkov luminescence imaging: a new tool for molecular imaging. Philosophical Transactions of the Royal Society a-Mathematical Physical and Engineering Sciences 369: 4605-4619.
30. de Jong M, Breeman WAP, Valkema R, Bernard BF, Krenning EP (2005) Combination radionuclide therapy using Lu-177- and Y-90-Labeled somatostatin analogs. Journal of Nuclear Medicine 46: 13S-17S.
31. Siegel JA, Stabin MG (1994) Absorbed Fractions for Electrons and Beta-Particles in Spheres of Various Sizes. Journal of Nuclear Medicine 35: 152-156.
32. Bouchet LG, Bolch WE, Goddu SM, Howell RW, Rao DV (2000) Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. Journal of Nuclear Medicine 41: 682-687.
33. Shank B, Chu FCH, Dinsmore R, Kapoor N, Kirkpatrick D, et al. (1981) Hyperfractionated Total-Body Irradiation for Bone-Marrow Transplantation. 3. Results in 70 Leukemia Patients with Allogeneic Transplants. International Journal of Radiation Oncology Biology Physics 7: 1240-1240.
34. Socie G, Devergie A, Girinsky T, Reiffers J, Vernant JP, et al. (1991) Influence of the Fractionation of Total-Body Irradiation on Complications and Relapse Rate for Chronic Myelogenous Leukemia. International Journal of Radiation Oncology Biology Physics 20: 397-404.
35. Cosset JM, Baume D, Pico JL, Shank B, Girinski T, et al. (1989) Single Dose versus Hyperfractionated Total-Body Irradiation Before Allogeneic Bone-Marrow Transplantation - a Non-Randomized Comparative-Study of 54 Patients at the Institut Gustave-Roussy. Radiotherapy and Oncology 15: 151-160.
36. Vanos R, Thames HD, Konings AWT, Down JD (1993) Radiation Dose-Fractionation and Dose-Rate Relationships for Long-Term Repopulating Hematopoietic Stem-Cells in a Murine Bone-Marrow Transplant Model. Radiation Research 136: 118-125.